20. ANALYSIS OF NET FUNDS
31 December Cashflow Acquisitions Non-cash Exchange 31 December 31 December
1996 changes movements 1997 1997
IR£ IR£ IR£ IR£ IR£ IR£ US$
Cash 2,904,847 (959,920 ) - - 43,295 1,988,222 2,827,251
Liquid resources 402,591 (37,713 ) - 688,763 (35,608 ) 1,018,033 1,447,643
Long term debt
- current portion
- (157,520 ) - - - (157,520 ) (223,993 )
Long term debt - (1,258,873 ) (1,136,497 ) - (135,830 ) (2,531,200 ) (3,599,365 )
Finance leases - 10,977 - (53,830 ) - (42,853 ) (60,937 )
________ ________ ________ ________ ________ ________ ________
Net funds 3,307,438 (2,403,049 ) (1,136,497 ) 634,933 (128,143 ) 272,682 390,599
________ ________ ________ ________ ________ ________ ________
31 December Cashflow Acquisitions Non-cash Exchange 31 December 31 December
1995 changes movements 1996 1996
IR£  IR£  IR£  IR£  IR£  IR£  US$
Cash 4,660,422 (1,557,575 ) - - (198,000 ) 2,904,847 4,130,692
Liquid resources 37,970 20,436 - 344,185 - 402,591 572,484
Long term debt
- current portion
(28,238 ) 28,238 - - - - -
Long term debt - - - - - - -
Finance leases (8,741 ) 8,741 - - - - -
________ ________ ________ ________ ________ ________ ________
Net funds 4,661,413 (1,500,160 ) - 344,185 (198,000 ) 3,307,438 4,703,176
________ ________ ________ ________ ________ ________ ________

 

31 December Cashflow Acquisitions Non-cash Exchange 31 December 31 December
1994 changes movements 1995 1995
IR£  IR£  IR£  IR£  IR£  IR£  US$
Cash 197,313 4,463,814 - - (705 ) 4,660,422 6,627,120
Liquid resources 117,068 (805,632 ) - 742,391 (15,857 ) 37,970 53,993
Long term debt
- current portion
(54,407 ) 53,841 - (27,672 ) - (28,238 ) (40,154 )
Long term debt (27,672 ) - - 27,672 - - -
Finance leases (31,192 ) 22,451 - - - (8,741 ) (12,430 )
________ ________ ________ ________ ________ ________ ________
Net funds 201,110 3,734,474 - 742,391 (16,562 ) 4,661,413 6,628,529
________ ________ ________ ________ ________ ________ ________

 

21. ACQUISITION OF SUBSIDIARY UNDERTAKINGS

On 1 January 1997 the Company acquired the entire issued share capital of Clark Laboratories, Inc. for a total consideration of IR£5,312,951 (US$7,550,016). The consideration was satisfied by cash and the issue of shares by the Company to the common stock holders of Clark Laboratories, Inc. Acquisition expenses amounted to IR£76,039 (US$108,127). On 1 July 1997 the Company acquired the entire issued share capital of Centocor UK Holdings Limited for a total consideration of IR£4,129,403 (US$5,872,011). The consideration was satisfied by cash and deferred consideration. Acquisition expenses amounted to IR£76,212 (US$108,373).

 

Clark Centocor Total Total
Laboratories Inc UK Holdings Ltd
IR£ IR£ IR£ US$
Investments 130,380 - 130,380 185,400
Tangible fixed assets 791,226 251,428 1,042,654 1,482,654
Intangible assets 0 31,464 31,464 44,742
Stocks 1,064,578 771,004 1,835,582 2,610,197
Debtors 678,864 937,676 1,616,540 2,298,720
Creditors (1,746,736 ) (2,079,778 ) (3,826,514 ) (5,441,303 )
________ ________ ________ ________
Net assets (liabilities) acquired at fair value 918,312 (88,206 ) 830,106 1,180,410
Goodwill 4,394,639 4,217,609 8,612,248 12,246,617
________ ________ ________ ________
Consideration 5,312,951 4,129,403 9,442,354 13,427,027
________ ________ ________ ________

 

Satisfied by: Clark Centocor Total Total
Laboratories Inc UK Holdings Ltd
IR£ IR£ IR£ US$
Cash payment including costs 1,200,835 2,054,354 3,255,189 4,628,879
Cash acquired (37,747 ) (1,124 ) (38,871 ) (55,275 )
________ ________ ________ ________
Net cash outflow 1,163,088 2,053,230 3,216,318 4,573,604
Loans acquired 1,136,497 0 1,136,497 1,616,099
Shares issued 2,380,455 0 2,380,455 3,385,007
Option consideration 632,911 0 632,911 899,999
Deferred considerations 0 2,076,173 2,076,173 2,952,318
________ ________ ________ ________
Consideration 5,312,951 4,129,403 9,442,354 13,427,027
________ ________ ________ ________

The subsidiary undertakings acquired during the year contributed IR£374,491 (US$532,526) to the Company's net operating cash flows, paid IR£111,193 (US$158,116) in respect of net returns on investment and servicing of finance, utilised IR£451,560 (US$642,118) for capital expenditure and financial investment, and had inflows of IR£179,117 (US$254,704) from increases in long term debt

Goodwill written off during the year in respect of acquisitions of subsidiary undertakings amounted to IR£8,612,248(US$12,246,617) and comprises:

 

Book Revaluations Accounting Other Other Fair Consideration Goodwill Goodwill
Values Policy Adjustments Adjustments Value
Alignment
IR£ IR£ IR£ IR£ IR£ IR£ IR£ IR£ US$
Clark Laboratories Inc.
Tangible Fixed Assets 874,666 (83,440 ) A 0 0 0 791,226
Intangible Fixed Assets 553,880 (553,880 ) B 0 0 0 0
Investments 130,380 0 0 0 0 130,380
Working Capital 1,098,888 0 (854,700 ) C (247,482 ) G 0 (3,294 )
_______ _______ _______ _______ _______ _______ _______ _______ _______
2,657,814 (637,320 ) (854,700 ) (247,482 ) 0 918,312 (5,312,951 ) (4,394,639 ) (6,249,177 )
_______ _______ _______ _______ _______ _______ _______ _______ _______
Centocor UK Holdings Limited
Tangible Fixed Assets 1,014,693 (763,265 ) D 0 0 0 251,428
Intangible Fixed Assets 110,456 0 0 (78,992 ) B 0 31,464
Working Capital 1,621,458 0 (781,938 ) E (71,951 ) F (1,138,667 ) G (371,098 )
_______ _______ _______ _______ _______ _______ _______ _______ _______
2,746,607 (763,265 ) (781,938 ) (150,943 ) (1,138,667 ) (88,206 ) (4,129,403 ) (4,217,609 ) (5,997,440 )
_______ _______ _______ _______ _______ _______ _______ _______ _______
Total (5,404,421 1,400,585 ) (1,636,638 ) (398,425 ) (1,138,667 ) (830,106 ) (9,442,354 ) (8,612,248 ) (12,246,617 )
_______ _______ _______ _______ _______ _______ _______ _______ _______

 

The book value of the assets and liabilities shown above have been taken from the management accounts of the acquired businesses at the date of acquisition.

The fair value adjustments above principally arise for the following reasons:

A. Revaluation representing the restatement of freehold property acquired to estimated market value.

B. Write down of capitalised intangibles following assessment of their realisable value.

C. Write down of stock following an assessment of the realisable value of finished goods, work in progress and raw materials and reflection of group policy in respect of recognition of sales income.

D. Write down of fixed assets following a physical verification exercise and assessment of the realisable value of certain assets.

E. Write down of stock following an assessment of the realisable value of finished goods, work in progress and raw materials.

F. Write down of debtors following an assessment of the estimated recoverable value.

G. Recognition of unprovided amounts in respect of onerous contracts and other liabilities.

22. PRE-ACQUISITION PROFIT AND LOSS DETAILS PERTAINING TO CERTAIN ACQUISITIONS

The unaudited US$ and Stg£ profit and loss details have been translated at the year end 1997 at the US dollar and sterling rates of US$1.4245 to IR£1 and Stg£0.89 to IR£1 respectively. The financial information has been prepared in accordance with generally accepted accounting practices and under the under the accounting policies of the companies prior to acquisition.

 

Clark Laboratories Inc. Clark Laboratories Inc.
Acquisition date 1 January 1997 1 January 1997
Previous year end 30 June 1996 30 June 1996
Profit after taxation IR£ US$
1 July 1996 to 31 December 1996 171,371 243,690
Year ended 30 June 1996 166,718 237,073
Additional disclosures - pre-acquisition period
Summarised profit and loss statements
Turnover 1,593,949 2,266,595
________ ________
Operating loss (59,396 ) (84,461 )
Interest and other income 353,855 503,182
Interest payable and similar charges (59,882 ) (85,152 )
________ ________
Profit on ordinary activities before taxation 234,577 333,569
Taxation (63,206 ) (89,879 )
________ ________
Profit on ordinary activities after taxation 171,371 243,690
________ ________

 

The profit attributable to ordinary shareholders for the pre-acquisition period is the same as the total recognised gains and losses for that period.

 

Centocor UK Holdings Ltd. Centocor UK Holdings Ltd.
Acquisition date 1 July 1997 1 July 1997
Previous year end 31 December 1996 31 December 1996
IR£ US$
Profit (loss) after taxation
1 January 1997 to 30 June 1997 164,049 233,278
Year ended 31 December 1996 (53,932 ) (76,691 )
Additional disclosures - pre-acquisition period
Summarised profit and loss statements
Turnover 2,181,264 3,101,757
________ ________
Operating profit 159,466 226,761
Interest and other income 6,708 9,539
Interest payable and similar charges (2,125 ) (3,022 )
________ ________
Profit on ordinary activities before taxation 164,049 233,278
Taxation - -
________ ________
Profit on ordinary activities after taxation 164,049 233,278
________ ________

 

The profit attributable to ordinary shareholders for the pre-acquisition period is the same as the total recognised gains and losses for that period.

23. SUPPLEMENTARY CASH FLOW INFORMATION

(a) Purchase of tangible fixed assets

31 December 31 December 31 December 31 December
1995 1996 1997 1997
IR£ IR£ IR£ US$
Additions to tangible fixed assets 87,612 275,179 2,504,216 3,560,995
Less new finance leases - - (53,830 ) (76,546 )
________ ________ ________ ________
87,612 275,179 2,450,386 3,484,449
________ ________ ________ ________

(b) Management of liquid resources

Cash flows from the use of liquid resources have primarily arisen from the sale of equity investments.

24. COMMITMENTS AND CONTINGENCIES

(a) Capital Commitments

The capital commitments of the group were as follows

31 December 31 December 31 December
1996 1997 1997
IR£ IR£ US$
Contracted for - 1,050,000 1,493,100
Authorised, not contracted for - 150,000 213,300
________ ________ ________
- 1,200,000 1,706,400
________ ________ ________

 

(b) Operating lease commitments payable during the next twelve months amount to IR£281,831 (US$400,764) payable on the lease of buildings at Dublin, Ireland and at Guildford, United Kingdom which expire in more than five years.

(c) During 1995 the Company entered into a licence agreement which provided for the back payment of royalties on sales of the Company's pregnancy test. The agreement also provided for the payment of royalties on future sales of certain products of the Company.

(d) Under agreements between group companies and Forbairt, grants amounting to IR£505,000 (US$718,110) have been received or are receivable which may be revoked, cancelled or abated in certain circumstances.

(e) Under agreements between a group company and the Irish Trade Board, a loan amounting to IR£131,782 (US$187,394) is payable which may be required to be repayed in full in certain circumstances.

(f) The Company has guaranteed the bank borrowings of subsidiary undertakings up to the amount of IR£2,688,720 (US$3,823,360).

(g) Pursuant to the provisions of Section 17, Companies (Amendment) Act, 1986, the Company has guaranteed the liabilities of certain of its subsidiary undertakings in the Republic of Ireland for the financial year to 31 December, 1997 and as a result such subsidiary undertakings have been exempted from the filing provisions of Section 7, Companies (Amendment) Act, 1986.

25. PENSION SCHEME

The Group operates a defined contribution pension scheme for its full-time employees. The benefits under this scheme are financed by Group and employee contributions. Total contributions made by the Group in the financial year and charged against income amounted to IR£181,704 (US$258,383) - December 31, 1996 IR£38,187 (US$54,302).

26. DIFFERENCES BETWEEN IRISH AND US GENERALLY ACCEPTED ACCOUNTING PRINCIPLES

The Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the Republic of Ireland ("Irish GAAP"), which differ in certain significant respects from accounting principles generally accepted in the United States ("US GAAP"). These differences relate principally to the following items and the necessary adjustments are shown in the table set out below;

(1) Stock Compensation:

In contrast to Irish GAAP, US GAAP requires that the grant of share options exercisable at prices per share less than the fair market value of the shares at the time of the grant of the options be accounted for as compensation expense to be recognised over the related vesting period.

(2) Goodwill:

Under Irish GAAP, goodwill may be either written off immediately on completion of the acquisition against shareholders' equity, or capitalised in the balance sheet and amortised through the income statement on a systematic basis over its useful economic life. Under US GAAP, accounting for goodwill as an offset against shareholders' equity is not permitted; rather, goodwill must be amortised over the period of its expected useful life, subject to a maximum write off period of 40 years, through the income statement. For the purposes of the reconciliation a useful life of 10 years has been adopted for goodwill.

(3) Cash Flow Statements:

The consolidated statement of cash flows prepared under Irish GAAP presents substantially the same information as that required under US GAAP by SFAS 95 "Statement of Cash Flows". This standard differs, however, with regard to the classification of items within the statements and as regards the definition of cash. Under US GAAP, cash equivalents would not include bank overdrafts. The movements on such bank overdrafts are required to be included in financing activities under SFAS 95. Under US GAAP short term investments with a maturity of three months or less at the date of acquisition are included in cash equivalents. Under Irish GAAP, movements in short term investments are classified as management of liquid resources.

Under Irish GAAP, cash flows are presented separately for operating activities, returns on investments and servicing of finance, taxation, capital expenditure and financial investment, equity dividends paid, management of liquid resources and financing. US GAAP, however, requires only three categories of cash flow activity to be reported: operating, investing and financing. Cash flows from taxation and returns on investments and servicing of finance shown under Irish GAAP would, with the exception of preference dividends paid, be included as operating activities under US GAAP. The payment of dividends would be included as a financing activity under US GAAP. Under US GAAP, capitalised interest is treated as a part of the cost of the asset to which it relates and is thus included as part of investing cash flows; under Irish GAAP all interest is treated as part of returns on investments and servicing of finance.

(4) Share Capital Not Paid:

Under Irish GAAP, unpaid share capital is classified as a receivable under current assets. Under US GAAP, share capital receivable should be reported as a reduction to Shareholders' Equity.

(5) Recognition of Escrow Income:

Under Irish GAAP, the Company has recognised as revenue amounts due to be released from an Escrow account in 1997. Under US GAAP such amounts are not recognisable until received.

 

CUMULATIVE EFFECT ON 31 December 31 December 31 December
SHAREHOLDERS' EQUITY 1996 1997 1997
IR£ IR£ US$
Total shareholders' equity before
minority interests under Irish GAAP 6,248,547 4,996,280 7,104,711
US GAAP adjustments:
Goodwill 5,357,620 12,783,762 18,178,706
Share capital not paid (65,234 ) (517,624 ) (736,061 )
Adjustment for amount due from escrow account (311,625 ) (877,501 ) (1,247,806 )
________ ________ ________
Shareholders' equity under US GAAP 11,229,308 16,384,917 23,299,550
________ ________ ________

 

EFFECT ON NET PROFIT (LOSS) 31 December 31 December 31 December 31 December
1995 1996 1997 1997
IR£ IR£ IR£ US$
Profit (loss) on ordinary activities after
taxation under Irish GAAP (519,129 ) (468,204 ) 849,697 1,208,269
US GAAP adjustments:
Goodwill amortisation
(693,327 ) (693,491 ) (1,186,106 ) (1,686,643 )
Stock compensation (252,958 ) (167,511 ) (469,765 ) (668,006 )
Amount due from escrow account - (311,625 ) (500,000 ) (711,000 )
________ ________ ________ ________
Loss under US GAAP (1,465,414 ) (1,640,831 ) (1,306,174 ) (1,857,380 )
________ ________ ________ ________
Loss per ordinary share (0.13 ) (0.10 ) (0.07 ) (0.10 )
Weighted average number of ordinary shares 11,135,753 16,119,559 19,108,363 19,108,363

 

27. GROUP UNDERTAKINGS

Name and
registered office
Principal activity Principal Country
of incorporation
and operation
Group
% holding
Holding Company
Trinity Biotech plc
Bray Business Park
Bray
Co. Wicklow, Ireland
Investment
and holding
company
Ireland
Subsidiary Undertakings
Trinity Biotech Inc.
(Formerly Disease Detection International Inc.)
2 Thomas
Irvine
California, USA.
Sale of pregnancy
and diagnostic tests
U.S.A. 100%
Trinity Biotech (USA) Corp.
(Formerly Clark Laboratories Inc.)
Girts Road
Jamestown
New York, USA
Manufacture and sale of diagnostic test kits U.S.A 100%
FHC Corporation
2 Thomas
Irvine
California, USA
Non-trading U.S.A. 100%
Trinity Biotech Manufacturing Limited
Bray Business Park
Bray
Co. Wicklow, Ireland
Manufacture and
sale of diagnostic
test kits
Ireland 100%
Trinity Research Limited
Bray Business Park
Bray
Co. Wicklow, Ireland
Research and
development
Ireland 100%
Trinity Biotech Sales Limited
Bray Business Park
Bray
Co. Wicklow, Ireland
Non-trading  Ireland 100%
Flambelle Limited
16 Fitzwilliam Place
Dublin, Ireland
Non-trading Ireland 100%
Eastcourt Limited
Chichester House
278/282 High Holborn
London, UK
Non-trading UK 100%
Trinity Biotech UK Holdings Ltd
(Formerly Centocor UK Holdings Ltd)
Captia House
Shalford
Guildford
Surrey, UK
Holding Company UK 100%
Trinity Biotech UK Ltd
(Formerly Centocor UK Limited)
Captia House
Shalford
Guildford
Surrey, UK
Manufacture and
sale of diagnostic
test kits
UK 100%

 

28. FINANCIAL ASSETS 31 December 31 December 31 December
1996 1997 1997
IR£ IR£ US$
Shares in Selfcare Inc. - 1,391,402 1,978,574
Shares in Trinity Biotech Inc. (formerly DDI) 7,442,334 7,442,334 10,582,999
Shares in Centocor UK Holdings Ltd - 4,130,461 5,873,515
Shares in Trinity Biotech (USA) Corp. - 4,214,201 5,992,594
Shares in Trinity Research Ltd. 102 102 145
Shares in Trinity Biotech Manufacturing Ltd. 2 2 3
Shares in Trinity Biotech Sales Ltd. 2 2 3
Shares in Flambelle Ltd. 100 100 142
Shares in Eastcourt Ltd. 100 100 142
Provision for diminution in value
of shares in Trinity Biotech Inc.
(3,000,000 ) (3,000,000 ) (4,266,000 )
Unlisted investment in CLI Oncology - 283,434 403,043
________ ________ ________
Balance at end of period 4,442,640 14,462,138 20,565,160
________ ________ ________

 

29. DEBTORS AND PREPAYMENTS 31 December 31 December 31 December
(Amounts falling due within one year) 1996 1997 1997
IR£ IR£ US$
Prepayments 100,751 29,225 41,558
Called up share capital not paid 65,233 517,624 736,061
________ ________ ________
165,984 546,849 777,619
________ ________ ________

NEXT    BACK TO ANNUAL REPORT